Histologic grade is a better predictor of specific survival than Ki67 in localized ER+/HER2-breast cancer: a real-world study

被引：0
|
作者：
Sanchez, Cesar
Alejandro, Cataldo
Walbaum, Benjamin
Acevedo, Francisco
Constabel, Christine
Saure, Antoine
Rey, Pablo
机构：
来源：
CANCER RESEARCH | 2024年 / 84卷 / 09期
关键词：
D O I：
10.1158/1538-7445.SABCS23-PO1-18-02
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
PO1-18-02
引用
收藏
页数：2
相关论文
共 50 条
  • [1] Intrinsic subtypes and risk scores in ER+/HER2-Breast Cancer: a comparison of Prosigna and OncotypeDX risk categories with Ki67
    Sinn, P.
    Schneeweiss, A.
    Endris, V.
    Penzel, R.
    Schirmacher, P.
    Kirchner, M.
    Stenzinger, A.
    BREAST, 2017, 32 : S105 - S105
  • [2] Real World Data on Neoadjuvant Endocrine Treatment and Ki67 Assessment in ER+/HER2-Breast Cancer. Results from a Single-Institution Prospective Cohort Study
    Marti, Covadonga
    Frias, Laura
    Loayza, Adolfo
    Moreno, Elisa
    Melendez, Marcos
    Sanchez-Mendez, Jose Ignacio
    CANCER RESEARCH, 2023, 83 (05)
  • [3] The Role of Ki-67 in HR+/HER2-Breast Cancer: A Real-World Study of 956 Patients
    Ma, Qin
    Liu, Yao-Bang
    She, Tong
    Liu, Xin-Lan
    BREAST CANCER-TARGETS AND THERAPY, 2024, 16 : 117 - 126
  • [4] Real-world aromatase inhibitor use and failure in women with metastatic ER+/HER2-breast cancer.
    Landsman-Blumberg, Pamela
    Namjoshi, Madhav
    Thomson, Erin
    Johnson, William
    JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (15)
  • [5] Assessment of tumor proliferation by mitotic activity index, phosphohistone H3 and Ki67 in early stage ER+/Her2-breast cancer
    van Steenhoven, Julia E. C.
    Kuijer, Anne
    van Leeuwen, A. M.
    van Gorp, Joost M.
    van Diest, Paul J.
    van Dalen, Thijs
    CANCER RESEARCH, 2020, 80 (04)
  • [6] Age, Ki-67, Nodal pCR and overall survival following Neoadjuvant Chemotherapy for Node Positive ER+/Her2-Breast Cancer
    Moldoveanu, Dan
    Goetz, Matthew P.
    Hoskin, Tanya L.
    Day, Courtney N.
    Boughey, Judy C.
    CANCER RESEARCH, 2023, 83 (05)
  • [7] Ki67 Gene Expression Was Associated with Complete Response to Neoadjuvant Chemotherapy but with Worse Survival in ER+/HER2Breast Cancer
    Chida, Kohei
    Wu, Rongrong
    Roy, Arya Mariam.
    Yan, Li
    Ishikawa, Takashi
    Hakamada, Kenichi
    Takabe, Kazuaki
    ANNALS OF SURGICAL ONCOLOGY, 2024, 31 (01) : S91 - S91
  • [8] ROLE OF KI67 IN PREDICTING SURVIVAL IN RH+/HER2-BREAST CANCER ACCORDING TO AXILLARY NODAL INVOLVEMENT
    Mejri, N.
    Berrazega, Y.
    Rachdi, H.
    Harhira, I.
    Boussen, H.
    INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER, 2021, 31 : A33 - A33
  • [9] ER+/HER2+ Breast Cancer Has Different Metastatic Patterns and Better Survival Than ER-/HER2+ Breast Cancer
    Arciero, Cletus A.
    Guo, Yi
    Jiang, Renjian
    Behera, Madhusmita
    O'Regan, Ruth
    Peng, Limin
    Li, Xiaoxian
    CLINICAL BREAST CANCER, 2019, 19 (04) : 236 - 245
  • [10] Reliability of Ki67-Labeling Index in Core Needle Biopsy Specimens of ER+/HER2-Breast Cancers
    Fukaya, Yumi
    Wakahara, Makoto
    Hosoya, Keiko
    Nouchi, Naoko
    Umekita, Yoshihisa
    PATHOLOGY INTERNATIONAL, 2025,
12345